Gilead Stock Today

GILD
 Stock
  

USD 61.60  0.51  0.83%   

Market Performance
1 of 100
Odds Of Distress
Less than 1
Gilead Sciences is trading at 61.60 as of the 8th of August 2022, a 0.83 percent up since the beginning of the trading day. The stock's lowest day price was 60.82. Gilead Sciences has a very small chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. Equity ratings for Gilead Sciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of July 2022 and ending today, the 8th of August 2022. Click here to learn more.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company was incorporated in 1987 and is headquartered in Foster City, California. The company has 1.25 B outstanding shares of which 16.56 M shares are currently shorted by private and institutional investors with about 2.44 trading days to cover. More on Gilead Sciences

Gilead Sciences Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Gilead Sciences' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Gilead Sciences or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Gilead Sciences is unlikely to experience financial distress in the next 2 years
Gilead Sciences has a very strong financial position based on the latest SEC filings
Over 82.0% of the company shares are owned by institutional investors
On 29th of June 2022 Gilead Sciences paid $ 0.73 per share dividend to its current shareholders
Latest headline from www.investing.com: Stock Market Today Dow Delivers Swashbuckling Gains as Earnings Shine By Investing.com - Investing.com
Chairman and CEOJohn Martin
SEC FilingsGilead Sciences Security & Exchange Commission EDGAR Reports
Thematic Ideas
(view all).
Fama & French Classification
Average Analyst Recommendation
Analysts covering Gilead Sciences report their recommendations after researching Gilead Sciences' financial statements, talking to executives and customers, or listening in on Gilead Sciences' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Gilead Sciences. The Gilead consensus assessment is calculated by taking the average forecast from all of the analysts covering Gilead Sciences.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Gilead Sciences based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Gilead Sciences financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Very StrongDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares1.2 B1.3 B
Slightly Down
Decreasing
Slightly volatile
Weighted Average Shares Diluted1.3 B1.3 B
Slightly Up
Decreasing
Slightly volatile
Net Cash Flow from Operations11.8 B11.4 B
Sufficiently Up
Increasing
Slightly volatile
Total Assets64 B68 B
Notably Down
Increasing
Slightly volatile
Total Liabilities43.1 B46.9 B
Significantly Down
Increasing
Slightly volatile
Current Assets19.2 B14.8 B
Significantly Up
Increasing
Slightly volatile
Current Liabilities11 B11.6 B
Notably Down
Increasing
Slightly volatile
Total Debt26 B26.7 B
Fairly Down
Increasing
Slightly volatile
Return on Average Assets0.120.092
Significantly Up
Decreasing
Slightly volatile
Gross Margin0.860.758
Moderately Up
Increasing
Slightly volatile
Asset Turnover0.430.404
Notably Up
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Gilead Sciences' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Gilead Sciences' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Gilead Sciences' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Gilead Sciences' bond ratings measure its overall creditworthiness, which in many ways corresponds to the cost of borrowing for an issuer. These ratings assign a letter grade to all of Gilead Sciences' outstanding corporate bonds that indicate their credit quality. We use reports published by private self-sufficient rating services such as Standard & Poor's or Fitch Ratings Inc. to evaluate a bond issuer's financial strength or its ability to pay a bond's principal and interest.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Gilead Sciences' financial leverage. It provides some insight into what part of Gilead Sciences' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Gilead Sciences' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Gilead Sciences deploys its capital and how much of that capital is borrowed.
Liquidity
Gilead Sciences cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 26.21 B in liabilities with Debt to Equity (D/E) ratio of 1.32, which is about average as compared to similar companies. Gilead Sciences has a current ratio of 1.45, which is within standard range for the sector. Debt can assist Gilead Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, Gilead Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Gilead Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Gilead to invest in growth at high rates of return. When we think about Gilead Sciences' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

11.78 Billion
Gilead Sciences (GILD) is traded on NASDAQ Exchange in USA. It is located in 333 Lakeside Drive, Foster City, CA 94404, United States and employs 14,400 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with current market capitalization of 76.63 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Gilead Sciences's market, we take the total number of its shares issued and multiply it by Gilead Sciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Gilead Sciences conducts business under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 1.25 B outstanding shares of which 16.56 M shares are currently shorted by private and institutional investors with about 2.44 trading days to cover. Gilead Sciences currently holds about 6.02 B in cash with 10.61 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.8.
Check Gilead Sciences Probability Of Bankruptcy
Ownership
Gilead Sciences secures a total of 1.25 Billion outstanding shares. The majority of Gilead Sciences outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Gilead Sciences to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Gilead Sciences. Please pay attention to any change in the institutional holdings of Gilead Sciences as this could imply that something significant has changed or about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.

Ownership Allocation (%)

Check Gilead Ownership Details

Gilead Stock Price Odds Analysis

What are Gilead Sciences' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Gilead Sciences jumping above the current price in 90 days from now is about 49.2%. The Gilead Sciences probability density function shows the probability of Gilead Sciences stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Gilead Sciences has a beta of 0.432. This usually indicates as returns on the market go up, Gilead Sciences average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Gilead Sciences will be expected to be much smaller as well. Additionally, the company has an alpha of 0.0303, implying that it can generate a 0.0303 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 61.6HorizonTargetOdds Above 61.6
50.35%90 days
 61.60 
49.20%
Based on a normal probability distribution, the odds of Gilead Sciences to move above the current price in 90 days from now is about 49.2 (This Gilead Sciences probability density function shows the probability of Gilead Stock to fall within a particular range of prices over 90 days) .

Gilead Sciences Historical Income Statement

Gilead Sciences Income Statement is one of the three primary financial statements used for reporting Gilead's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Gilead Sciences revenue and expense. Gilead Sciences Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Gilead Sciences Earning Before Interest and Taxes EBIT is projected to increase significantly based on the last few years of reporting. The past year's Earning Before Interest and Taxes EBIT was at 9.3 Billion. The current year Gross Profit is expected to grow to about 21.2 B, whereas Cost of Revenue is forecasted to decline to about 5.8 B. View More Fundamentals

Gilead Stock Against Markets

Picking the right benchmark for Gilead Sciences stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Gilead Sciences stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Gilead Sciences is critical whether you are bullish or bearish towards Gilead Sciences at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Gilead Sciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Holdings Now

   

Portfolio Holdings

Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
All  Next Launch Module

Gilead Sciences Corporate Directors

Gilead Sciences corporate directors refer to members of a Gilead Sciences board of directors. The board of directors generally takes responsibility for the Gilead Sciences' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Gilead Sciences' board members must vote for the resolution. The Gilead Sciences board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Gayle Wilson - Independent DirectorProfile
Jacqueline Barton - DirectorProfile
John Madigan - Independent DirectorProfile
Kevin Lofton - Independent DirectorProfile

Invested in Gilead Sciences?

You need to understand the risk of investing before taking a position in Gilead Sciences. The danger of trading Gilead Sciences is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Gilead Sciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Gilead Sciences. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Gilead Sciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please check Risk vs Return Analysis. Note that the Gilead Sciences information on this page should be used as a complementary analysis to other Gilead Sciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for Gilead Stock analysis

When running Gilead Sciences price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Gilead Sciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.